ACS medicinal chemistry letters
Novel 2,4,6-Trisubstituted 1,3,5-Triazines as CX3CR1 Modulators for the Treatment of Cardiovascular Disorders.
Taoqian Zhao, Steven H Liang
Published: 202610.1021/acsmedchemlett.5c00691
Abstract
Open AccessThis patent application describes a novel series of 2,4,6-trisubstituted 1,3,5-triazines compounds represented by Formula I. These compounds hold promise for the treatment of cardiovascular disorders, including nonischemic dilated cardiomyopathy and heart failure.